ATE456363T1 - Trockenpulver-inhalator-formulierungen mit oberflächenmodifiziierten teilchen mit antihaftzusätzen - Google Patents

Trockenpulver-inhalator-formulierungen mit oberflächenmodifiziierten teilchen mit antihaftzusätzen

Info

Publication number
ATE456363T1
ATE456363T1 AT05808842T AT05808842T ATE456363T1 AT E456363 T1 ATE456363 T1 AT E456363T1 AT 05808842 T AT05808842 T AT 05808842T AT 05808842 T AT05808842 T AT 05808842T AT E456363 T1 ATE456363 T1 AT E456363T1
Authority
AT
Austria
Prior art keywords
dry powder
powder inhaler
modified particles
particles
inhaler formulations
Prior art date
Application number
AT05808842T
Other languages
German (de)
English (en)
Inventor
David Morton
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33548732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE456363(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Application granted granted Critical
Publication of ATE456363T1 publication Critical patent/ATE456363T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Steroid Compounds (AREA)
AT05808842T 2004-11-23 2005-11-23 Trockenpulver-inhalator-formulierungen mit oberflächenmodifiziierten teilchen mit antihaftzusätzen ATE456363T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0425758.0A GB0425758D0 (en) 2004-11-23 2004-11-23 Preparation of pharmaceutical compositions
PCT/GB2005/050211 WO2006056812A1 (en) 2004-11-23 2005-11-23 Dry powder inhaler formulations comprising surface-modified particles with anti- adherent additives

Publications (1)

Publication Number Publication Date
ATE456363T1 true ATE456363T1 (de) 2010-02-15

Family

ID=33548732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05808842T ATE456363T1 (de) 2004-11-23 2005-11-23 Trockenpulver-inhalator-formulierungen mit oberflächenmodifiziierten teilchen mit antihaftzusätzen

Country Status (16)

Country Link
US (4) US20080127972A1 (enExample)
EP (4) EP2311434B1 (enExample)
JP (2) JP5339401B2 (enExample)
CN (2) CN101106975A (enExample)
AT (1) ATE456363T1 (enExample)
CA (1) CA2589514C (enExample)
DE (1) DE602005019192D1 (enExample)
DK (2) DK2174653T3 (enExample)
ES (3) ES2490240T3 (enExample)
GB (1) GB0425758D0 (enExample)
HU (1) HUE027465T2 (enExample)
IN (1) IN2014CN04336A (enExample)
PL (3) PL2174653T3 (enExample)
PT (3) PT1814521E (enExample)
SI (2) SI2311434T1 (enExample)
WO (1) WO2006056812A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2708961T3 (es) 2000-11-30 2019-04-12 Vectura Ltd Composiciones farmacéuticas para inhalación
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
CA2519287A1 (en) 2003-03-27 2004-10-14 Bioactis Limited Powder medicine applicator for nasal cavity
US20120321717A1 (en) * 2003-04-14 2012-12-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0621957D0 (en) * 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
EP3053440B1 (en) * 2007-04-11 2020-08-12 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
EP2230934B8 (en) 2007-12-14 2012-10-24 AeroDesigns, Inc Delivering aerosolizable food products
JP5947543B2 (ja) 2008-07-18 2016-07-06 プロソニックス リミテッドＰｒｏｓｏｎｉｘ Ｌｉｍｉｔｅｄ 結晶化度を改善する方法
PT2410981T (pt) 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
GB0905840D0 (en) * 2009-04-06 2009-05-20 Sagentia Ltd Apparatus and methods
EP2421514A2 (en) * 2009-04-24 2012-02-29 Schering Corporation Agglomerate formulations useful in dry powder inhalers
EP2429495A4 (en) * 2009-05-15 2014-01-22 Shin Nippon Biomedical Lab Ltd INTRANASAL PHARMACEUTICAL COMPOSITION WITH IMPROVED PHARMACOKINETICS
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0918431D0 (en) 2009-10-21 2009-12-09 Prosonix Ltd Process for improving crystallinity
SG184352A1 (en) * 2010-04-01 2012-10-30 Chiesi Farma Spa Process for preparing carrier particles for dry powders for inhalation
UA111470C2 (uk) * 2010-04-21 2016-05-10 К'Єзі Фармачеутічі С.П.А. Спосіб отримання частинок зі зменшеними електростатичними зарядами
CN102309456B (zh) * 2010-07-02 2013-05-01 北京化工大学 一种厄贝沙坦纳微复合粉体与片剂及其制备方法
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
CA2809666C (en) * 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
US9642798B2 (en) * 2010-09-29 2017-05-09 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
PT3470057T (pt) * 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ITMI20120092A1 (it) * 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
PE20142342A1 (es) 2012-03-13 2015-01-16 Respivert Ltd FORMAS CRISTALINAS DE 6-(2-((4-AMINO-3-(3-HIDROXIFENIL)-1H-PIRAZOLO[3,4-d]PIRIMIDIN-1-IL)METIL)-3-(2-CLOROBENCIL)-4-OXO-3,4-DIHIDROQUINAZOLIN-5-IL)-N,N-BIS(2-METOXIETIL)HEX-5-INAMIDA COMO INHIBIDORES DE CINASA DE FOSFOINOSITIDA 3
US9763965B2 (en) 2012-04-13 2017-09-19 Glaxosmithkline Intellectual Property Development Limited Aggregate particles
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
CN103588846B (zh) * 2012-08-15 2016-08-03 重庆华邦制药有限公司 一种丙酸氟替卡松微粒的制备方法及其用途
BR112015010601B1 (pt) * 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
JP6116206B2 (ja) * 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
RU2015146871A (ru) 2013-04-01 2017-05-10 Пулматрикс, Инк. Сухие порошки с тиотропием
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
HUE039827T2 (hu) * 2013-07-11 2019-02-28 Chiesi Farm Spa Antikolinerg, kortikoszteroid és béta-adrenerg anyagokat tartalmazó száraz porkészítmény inhalálással történõ beadásra
EP3054948B1 (en) * 2013-10-08 2020-08-12 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CA2977083A1 (en) 2014-02-20 2015-08-27 Kambiz Yadidi Dry powder formulations for inhalation
WO2015154084A1 (en) 2014-04-04 2015-10-08 Lam Therapeutics, Inc. An inhalable rapamycin formulation for treating age-related conditions
EP3166641B1 (en) 2014-07-09 2018-09-12 Arven Ilac Sanayi Ve Ticaret A.S. A process for the preparation of formulations for inhalation
KR102603897B1 (ko) 2014-07-31 2023-11-20 벡추라 인코포레이티드 흡입용 건조 분말 제형
CN106604720B (zh) 2014-09-09 2020-03-10 维克多瑞有限公司 包含格隆铵的制剂、方法和设备
CN107249576A (zh) 2014-10-07 2017-10-13 拉姆医疗公司 用于治疗肺高压的可吸入雷帕霉素制剂
US20160119692A1 (en) * 2014-10-24 2016-04-28 Sunshine Partners LLC Interactive system and method for viewer selection of objects in context while viewing television
ES2841933T3 (es) 2014-10-31 2021-07-12 Univ Monash Formulación en polvo
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
US9585835B1 (en) * 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
CA3067011A1 (en) 2016-06-17 2017-12-21 Axon Enterprise, Inc. Systems and methods for aligning event data
JP2019524648A (ja) * 2016-06-30 2019-09-05 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム ニコチン粒子および組成物
SG11201809630RA (en) 2016-06-30 2018-11-29 Philip Morris Products Sa Nicotine particles
AU2017341815B2 (en) * 2016-10-14 2023-06-15 Pulmatrix Operating Company, Inc. Antifungal dry powders
JP7680823B2 (ja) * 2017-03-07 2025-05-21 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 吸入可能なニコチン製剤、およびその作製および使用方法
US11590298B2 (en) 2017-06-02 2023-02-28 Csp Technologies, Inc. Inhaler and methods of using and making same
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CN111315363B (zh) 2017-09-22 2022-10-11 奥迪托皮克股份有限公司 含有硬脂酸镁的干粉组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
JP2021509677A (ja) 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるオランザピンの鼻孔間送達
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
WO2023069028A1 (en) * 2021-10-20 2023-04-27 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
US12005185B2 (en) * 2021-12-17 2024-06-11 Belhaven BioPharma Inc. Medical counter measures including dry powder formulations and associated methods
WO2023128913A1 (en) * 2021-12-31 2023-07-06 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation
EP4551196A1 (en) 2022-07-04 2025-05-14 Hovione Scientia Limited Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation
CN115060832B (zh) * 2022-08-18 2022-11-29 上海奥科达生物医药科技有限公司 奥卡西平口服混悬液中奥卡西平及防腐剂含量检测方法
CN115770221A (zh) * 2022-12-29 2023-03-10 浙江上药九旭药业有限公司 银杏酮酯粉体、银杏酮酯滴丸剂及其制备方法
GB2641869A (en) 2023-08-30 2025-12-17 Envirohale Malta Holdings Ltd Nasal and pulmonary drug delivery
WO2025195446A1 (zh) * 2024-03-20 2025-09-25 浙江萃泽医药科技有限公司 一种可吸入的药物粉末制剂及其制备方法
CN119055610A (zh) * 2024-08-27 2024-12-03 江苏谦仁生物科技有限公司 一种阿昔莫司胶囊及其制备方法
CN119371006B (zh) * 2024-11-06 2025-07-04 北京城市排水集团有限责任公司 一种长效缓释型污泥脱氮菌群调节药剂及制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
DE69027319T2 (de) 1989-04-28 1996-11-21 Riker Laboratories Inc., Northridge, Calif. Inhalationsvorrichtung für trockenpulver
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US5292520A (en) 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
SA95160463B1 (ar) 1994-12-22 2005-10-04 استرا أكتيبولاج مساحيق للاستنشاق
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
FR2747311B1 (fr) 1996-04-10 1998-08-14 Pf Medicament Inhalateur a poudre et a air comprime
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6051257A (en) 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
EP0931595A1 (en) 1998-01-26 1999-07-28 Imra Europe S.A. A device for spraying a liquid
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
PT1283036E (pt) 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
DK1158958T3 (da) 1999-03-05 2007-10-08 Chiesi Farma Spa Forbedret pulverformulering til inhalering
MXPA01012106A (es) 1999-05-27 2003-06-30 Acusphere Inc Matrices porosas de farmaco y metodo de fabricacion de las mismas.
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
GB2353222B (en) 1999-06-23 2001-09-19 Cambridge Consultants Inhalers
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
US20010036481A1 (en) 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
JP2001151673A (ja) 1999-09-06 2001-06-05 Nikken Chem Co Ltd 吸入用粉末製剤の製造方法
JP2001072586A (ja) 1999-09-06 2001-03-21 Nikken Chem Co Ltd 吸入用粉末製剤及びその製造方法
CA2383466C (en) 1999-09-16 2009-08-25 Tanabe Seiyaku Co., Ltd. Aromatic nitrogen-containing 6-membered cyclic compounds
FI20002217A7 (fi) 1999-12-30 2001-07-01 Orion Yhtymae Oyj Inhalaatiopartikkelit
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
CZ20023637A3 (cs) 2000-04-07 2003-02-12 Tap Pharmaceutical Products, Inc. Deriváty apomorfinu a způsoby jejich použití
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
NZ521972A (en) 2000-04-17 2004-06-25 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
GB0010709D0 (en) * 2000-05-03 2000-06-28 Vectura Ltd Powders for use a in dry powder inhaler
EP1913939B1 (en) * 2000-06-27 2017-05-31 Vectura Limited Formulations for use in inhaler devices
GB2364919A (en) 2000-07-21 2002-02-13 Cambridge Consultants Inhalers
AU2001277230A1 (en) 2000-08-01 2002-02-13 Inhale Therapeutic Systems, Inc. Apparatus and process to produce particles having a narrow size distribution andparticles made thereby
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US20020086876A1 (en) 2000-11-15 2002-07-04 Ruff Dustin D. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
WO2002039879A2 (en) 2000-11-15 2002-05-23 Tap Pharmaceutical Products, Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
ES2689704T3 (es) * 2000-11-30 2018-11-15 Vectura Limited Partículas para usar en una composición farmacéutica
WO2002043701A2 (en) 2000-11-30 2002-06-06 Vectura Limited Method of making particles for use in a pharmaceutical composition
AU2002215114A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
ES2708961T3 (es) 2000-11-30 2019-04-12 Vectura Ltd Composiciones farmacéuticas para inhalación
PT2301524E (pt) 2000-12-27 2013-07-10 Gilead Sciences Inc Aztreonam inalável sem arginina para tratamento e prevenção de infecções bacterianas pulmonares
GB0109384D0 (en) * 2001-04-12 2001-05-30 Vectura Ltd Pharmaceutical products, preparation and uses thereof
GB2375308A (en) 2001-05-10 2002-11-13 Cambridge Consultants Inhalers
CA2444729A1 (en) 2001-05-10 2002-11-14 Vectura Delivery Devices Limited Inhalers
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
JP2005506323A (ja) * 2001-09-05 2005-03-03 ベクトゥラ・リミテッド 経口送達用機能性散剤
AU2003209475A1 (en) * 2002-03-07 2003-09-16 Vectura Limited Fast melt multiparticulate formulations for oral delivery
US20040003341A1 (en) 2002-06-20 2004-01-01 Koninklijke Philips Electronics N.V. Method and apparatus for processing electronic forms for use with resource constrained devices
WO2004032901A1 (en) * 2002-10-11 2004-04-22 Vectura Limited Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof
EP1617820B1 (en) * 2003-04-14 2018-03-21 Vectura Limited Dry power inhaler devices and dry power formulations for enhancing dosing efficiency
US20040204439A1 (en) 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
WO2004089374A1 (en) 2003-04-14 2004-10-21 Vectura Ltd Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
US20060292081A1 (en) * 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0330255D0 (en) 2003-12-31 2004-02-04 Vectura Ltd Multiparticulate formulations for oral delivery
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
EP2174653B1 (en) 2014-05-14
SI2174653T1 (sl) 2014-10-30
JP5339401B2 (ja) 2013-11-13
US9585834B2 (en) 2017-03-07
DE602005019192D1 (de) 2010-03-18
WO2006056812A1 (en) 2006-06-01
EP2311434B1 (en) 2015-07-08
IN2014CN04336A (enExample) 2015-09-04
EP2174653A1 (en) 2010-04-14
CN101106975A (zh) 2008-01-16
EP1814521A1 (en) 2007-08-08
JP2008520307A (ja) 2008-06-19
PT2174653E (pt) 2014-08-25
SI2311434T1 (sl) 2015-11-30
EP2949317B1 (en) 2017-01-04
DK2174653T3 (da) 2014-08-11
DK2311434T3 (en) 2015-10-05
GB0425758D0 (en) 2004-12-22
PT1814521E (pt) 2010-04-16
PL2174653T3 (pl) 2014-11-28
PL1814521T3 (pl) 2010-07-30
US20110236492A1 (en) 2011-09-29
EP2311434A1 (en) 2011-04-20
JP5579669B2 (ja) 2014-08-27
CN104146960A (zh) 2014-11-19
CA2589514A1 (en) 2006-06-01
ES2340599T3 (es) 2010-06-07
EP2949317A1 (en) 2015-12-02
ES2490240T3 (es) 2014-09-03
PL2311434T3 (pl) 2015-12-31
EP1814521B1 (en) 2010-01-27
US9642800B2 (en) 2017-05-09
US20170216203A1 (en) 2017-08-03
ES2548884T3 (es) 2015-10-21
US20080127972A1 (en) 2008-06-05
HUE027465T2 (en) 2016-09-28
PT2311434E (pt) 2015-10-23
US20160000709A1 (en) 2016-01-07
JP2011201925A (ja) 2011-10-13
CA2589514C (en) 2014-07-22

Similar Documents

Publication Publication Date Title
ATE456363T1 (de) Trockenpulver-inhalator-formulierungen mit oberflächenmodifiziierten teilchen mit antihaftzusätzen
MY150531A (en) Anti-cd79b antibodies and immunoconjugates and methods of use
EA201591729A1 (ru) Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства
BRPI0607728A2 (pt) complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado
WO2008084312A3 (en) Micronised particles of low-dosage strength active agents for powder formulations for inhalation
ITMI20051999A1 (it) Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
ATE453382T1 (de) Pulver zur nasalen verabreichung von wirkstoffen
DK1663155T3 (da) Tørpulversammensætning omfattende jetformalede partikler til lungeinhalation
ATE494030T1 (de) Pulverinhalator
NZ700875A (en) Pharmaceutical nanoparticles showing improved mucosal transport
MX2010008234A (es) Nueva dosificacion y formulacion.
MX2010008235A (es) Nueva dosificacion y formulacion.
MY144114A (en) Painting composition having improved rheological characteristics
EP2571486A4 (en) DRY POWDER INHALATION COMPOSITION
PA8633401A1 (es) Dispositivo inhalador de medicamentos
GEAP201814377A (en) Dry powder inhaler and inhalation actuated mechanism thereof
EA201000838A1 (ru) Плавленный керамический продукт, способ производства и применение
DE602004005462D1 (de) Medikamente zur inhalation mit betamimetika und einem anticholinergikum
WO2005041922A3 (en) Composition
EA200500389A1 (ru) Композиции для ингаляции
MX2015015150A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
WO2008066810A3 (en) Pleasant tasting dry powder compositions suitable for pulmonary delivery
GEP201706672B (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists
PL2051693T3 (pl) Kompozycja farmaceutyczna, łatwa do połknięcia i nie powodująca nieprzyjemnych odczuć w ustach, zawierająca cząstki z substancją czynną
DK2092838T3 (da) Tobaks-/katalysatorblandinger til reduktion af toksiske forbindelser i tobaksrøg

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1814521

Country of ref document: EP